Ph1 Trial Results of Dementia Drug Positive
  (1/12/22)
Anavex Life Sciences' study of Anavex 3-71 in frontotemporal dementia met primary and secondary safety endpoints, noted a Dawson James Securities report. More >

Cell Firm Joins With Food Co. to Create Meat Substitute
  (1/12/22)
Pluristem Therapeutics and Tnuva will incorporate a new company that will use its own funding and resources to develop cell-based synthetic meat products, noted a Dawson James Securities report. More >

Vaccine Maker Doses 1st Patient in Phase 1b Parkinson's Trial
Source: Streetwise Reports  (1/12/22)
Shares of new class synthetic vaccine developer Vaxxinity Inc. traded 23% higher after the company reported it has dosed the first patient in its Phase 1b UB-312 Parkinson's disease study. More >

Newrange Expands Gold Search in 2022
Source: Streetwise Reports  (1/11/22)
Newrange Gold Corp. is expanding its search for precious minerals from one project to three in 2022 and looking at the big picture at its flagship operation in Nevada. More >

Media Co. Gets New Listing on CSE
Source: Streetwise Reports  (1/11/22)
Mijem Newcomm Tech is going public to capitalize on the cryptocurrencies trend, given it now rewards users of its marketplace app with Bitcoin SV. More >

Financial Firm Recommends Royalty and Streaming Cos.
  (1/11/22)
These companies are attractive now because, unlike mining operators, they are insulated from inflationary costs, noted a BMO Capital Markets report. More >

Bitcoin Miner Announces Q4/21 Production, 2022 Outlook
  (1/11/22)
COVID and supply chain constraints hampered its Q4/21 production, but Riot Blockchain is bullish on its 2022 performance, noted a ROTH Capital Partners report. More >

Biotech Co. Partners With Life Sciences Firms
  (1/11/22)
2seventy entered agreements with Novo Nordisk and Genevant to get an in vivo gene editing treatment for hemophilia A developed, noted a Wedbush report. More >

Analyst Stands at Crossroads in 2022
Source: Michael Ballanger  (1/11/22)
With the accelerating involvement of government in the day-to-day behavior of all markets, it's a near-impossibility to forecast what will happen in 2022, Michael Ballanger says. More >

Gold Mining Co. to Trade on TSX.V, Sampling Results Positive
Source: Streetwise Reports  (1/11/22)
Reyna Gold, approved for listing on Toronto's Venture Exchange, finds high-grade gold in samples from La Gloria that highlight the project's potential. More >

HealthCare Solutions Co. Gains 8 Million New Members in 2021
Source: Streetwise Reports  (1/11/22)
Accolade Inc. shares rose 27% after the company reported Q3/22 financial results that included a 117% increase in YoY revenue. The firm highlighted that in calendar year 2021, its membership increased four-fold from 2 million to 10 million. More >

2022 to Be Catalyst Rich for Biopharma
  (1/10/22)
The potential stock-moving events for Infinity Pharmaceuticals this year include the launch of two clinical trials and readouts from four studies, noted an H.C. Wainwright & Co. report. More >

Enrollment Done for COVID-19 Drug Trial
  (1/10/22)
Part 2 of First Wave BioPharma's RESERVOIR trial of niclosamide to remove the SARS-CoV-2 virus from the GI tract is underway, noted a ROTH Capital Partners report. More >

Words With Friends & Grand Theft Auto in Gaming Merger
Source: Streetwise Reports  (1/10/22)
Social gamer Zynga traded 40% higher after the company agreed to be acquired by Take-Two Interactive Inc. in a combination stock and cash transaction for $9.861 per share. More >

The Critical Investor Shares His Top 7 Picks for 2022
Source: The Critical Investor  (1/9/22)
The Critical Investor was asked again by Streetwise Reports to provide his top 7 picks for the new year — at a point where the COVID-19 pandemic is playing out the Omicron variant, inflation is reaching levels not seen in decades, the Fed surprising the markets with a more hawkish stance than anticipated, with metal prices at very high levels although gold and silver seem to be consolidating and setting up for a breakout. More >

Co.'s samRNA Vaccines Protect Better Against COVID Variants
  (1/7/22)
Gritstone bio Inc.'s lower-dose samRNA vaccines include a broader immune response to SARS-CoV-2 and may provide better protection against emerging variants. BTIG research has issued a "Buy" rating for Gritstone bio. More >

AI Driven Drug Firm Partners With Merck
Source: Streetwise Reports  (1/7/22)
Shares of Absci Corp. rose 18% after the company reported it is collaborating with Merck & Co. to create enzymes using its deep-learning Integrated Drug Creationâ„¢ platform and Bionic Proteinâ„¢ technologies. More >

Logiq Board OKs Splitting Into 2 Companies
Source: Streetwise Reports  (1/6/22)
E-commerce customer acquisition solutions company Logiq Inc. plans to separate into two publicly traded companies this month, President and Executive Chairman Brent Suen says. More >

2022 Could See Shipping Co. Dividends, Buybacks
  (1/6/22)
Noble Capital Markets has an Outperform rating and a $45 per share price target on Euroseas Ltd. given the company's favorable outlook for 2022. More >

Silver, Gold Could Outperform Industrial Metals in 2022
  (1/6/22)
Mining companies finished 2021 strongly with a 7.3% gain in Q4/21, reported Noble Capital Markets in a research note. More >

Co. Partners to Test New Cancer Vaccines
  (1/6/22)
Genocea Biosciences Inc. is teaming up with Janssen Biotech to explore the immunogenicity of neoantigens and the role and impact of Inhibigensâ„¢ in potential vaccine therapies for cancer. H.C. Wainwright & Co. advised that it currently has a "Buy" rating on Genocea. More >

Medical Co. Strikes $3B Deal to Buy Digital Care Firm
Source: Streetwise Reports  (1/6/22)
Shares of Vocera Communications Inc. traded nearly 27% higher after the company reported it entered into a definitive agreement to be acquired by Stryker Corp. for $79.25 per share in cash. More >

Analyst Says Co.'s Stock Could Skyrocket
Source: Clive Maund  (1/6/22)
Analyst Clive Maund says Kainantu Resources Ltd.'s stock could take off if it makes a discovery at its properties in Papua New Guinea. More >

Chen Lin's Top 6 Investment Ideas
Source: Streetwise Reports  (1/5/22)
In a recent interview with Streetwise Reports, family assets manager and contributing writer, Chen Lin, shared the six (mostly mid-cap) companies that are his top investment picks for 2022. More >

New Muscular Dystrophy Drug Shows Promise
Source: Streetwise Reports  (1/5/22)
Edgewise Therapeutics shares traded 24% higher after the company reported its EDG-5506 significantly lowered muscle damage biomarkers in adults after just two weeks of dosing in its Becker muscular dystrophy trial. More >